Home / Company / Senior Management Team

Senior Management Team

​Invectys Inc. is led by a team of experienced industry professionals, combining vision, scientific knowledge and management skills.

Praveen Tyle, Ph.D., President & CEO

Ph.D. in pharmaceutics and pharmaceutical chemistry. Over 35 years of global pharmaceutical and biotechnology industry experience, including 25+ years in Senior Executive Management and has been responsible for development and commercialization of various pharmaceutical products. Also serves as an independent director of Eyegate Pharmaceuticals, Inc., Yolia Health, Lipomedix and Orient Europharma Ltd.

Pierre Langlade Demoyen, Ph.D., Co-founder & CEO, Invectys SA

M.D. & Ph.D. in immunology. A former laboratory head at the Institut Pasteur in Paris, Pierre Langlade Demoyen has published 70 scientific papers and was involved in the development of 10 patents.

Julien Caumartin, Ph.D., CSO

An immunologist for 15 years, 9 of which were being in charge of a research team involved in the development of new immunotherapies against cancer.

Rosemary Williams, CPA, Vice-President for Administration and Controller

35 years of accounting experience and organizational administration of both small and large companies, including 9 years as VP at Bellicum Pharmaceuticals and Sandhill Therapeutics.

Melissa Yang, Ph.D., Vice President, Scientific Affairs

Nearly 20 years of experience in R&D at all levels and across a broad range of indications, including assisting in Lexicon’s first drug to market. Her experience also includes 8 years’ experience in managing cross-functional R&D teams.

Thierry Huet, Ph.D., R&D Director

Ph.D. in virology. Extensive experience of more than 30 years in pharmaceutical and biotechnology R&D, including 10 years at Sanofi-Aventis as R&D manager. Thierry Huet has strong skills in the management of preclinical and clinical trials.

Virginie Leplat, COO

Extensive experience of more than 30 years in managing start-ups with focus on their growth and business organization, 25 of which in Life Sciences sector.